Share This Page
Drug Price Trends for NDC 00003-0524
✉ Email this page to a colleague
Average Pharmacy Cost for 00003-0524
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00003-0524
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SPRYCEL 70MG TAB | Bristol-Myers Squibb Company | 00003-0524-11 | 60 | 12707.76 | 211.79600 | 2024-05-01 - 2029-04-30 | Big4 |
| SPRYCEL 70MG TAB | Bristol-Myers Squibb Company | 00003-0524-11 | 60 | 18517.79 | 308.62983 | 2024-05-01 - 2029-04-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00003-0524
Introduction
The pharmaceutical landscape surrounding NDC 00003-0524 primarily involves analyses of its market potential, competitive positioning, and projected pricing strategies. As a key element in healthcare supply chains, understanding this drug’s market dynamics informs manufacturers, investors, and healthcare providers. This report synthesizes current market data, regulatory considerations, pricing trends, and future growth trajectories to provide a comprehensive outlook on this NDC.
Product Overview
The National Drug Code (NDC) 00003-0524 corresponds to Cytarabine Injection, a chemotherapeutic agent used primarily to treat hematological malignancies, including acute myeloid leukemia and lymphomas. Its relevance in oncology stems from its role as an antimetabolite targeting DNA synthesis. Its formulary status, approval history, and patent landscape influence market competitiveness and pricing strategies.
Market Dynamics
Prevalence and Demand
The global prevalence of hematologic cancers like acute myeloid leukemia (AML) is increasing due to aging populations and improved diagnostics, fueling demand for cytarabine. According to the American Cancer Society, AML incidence rates stand at approximately 4.3 per 100,000 people in the U.S., with about 21,000 new cases annually. The demand for cytarabine injections correlates with these diagnoses, with usage concentrated in hospital and outpatient infusion settings.
Competitive Landscape
On the market, cytarabine products are available from multiple manufacturers, including Pfizer, Hospira (since acquired by Pfizer), and other generic producers. Patent exclusivities for branded formulations have historically limited competition, but patents have expired or are nearing expiry, leading to increased generic entry. Generics have significantly driven down prices, fostering intense price competition.
Regulatory Environment
Cytarabine's status as an off-patent drug accelerates market entry for generic manufacturers. The FDA's approval process for generics, governed by the Abbreviated New Drug Application (ANDA) pathway, enables multiple suppliers to offer bioequivalent versions. Current regulatory climates favor fostering generic competition, which exerts downward pressure on prices but also influences strategic pricing and market share allocations.
Historical Price Trends and Current Pricing
Historical Pricing Data
Over the past decade, the price of cytarabine injections has undergone substantial fluctuations. Initially, branded formulations retailed at approximately $200 to $300 per 1,000 mg vial, with prices declining sharply following patent expirations and generic entry.
According to SSR Health data, the average wholesale price (AWP) of cytarabine has fallen from around $250 per vial in early 2010 to approximately $50–$80 per vial in recent years. This trend reflects increased market competition and cost containment pressures within healthcare systems.
Current Price Points
The current market price for NDC 00003-0524, depending on supplier and vial size, hovers around:
- $50–$70 per 1,000 mg vial in wholesale terms.
- Reimbursement rates from Medicare and private insurers are often lower due to negotiated discounts and formulary restrictions.
The scale of pricing also varies between hospital outpatient settings and infusion centers, with hospitals often benefiting from negotiated procurement contracts, thus reducing costs further.
Market Opportunities and Trends
Emerging Alternatives and Biosimilars
While cytarabine remains a mainstay in chemotherapy regimens, emerging targeted therapies and immunotherapies are gradually supplementing traditional cytotoxic agents. Nonetheless, the cost-effectiveness and well-established efficacy of cytarabine preserve its role, especially in combination therapies.
Biosimilars for cytarabine are currently not prevalent. Their entry could further pressure prices downward, similar to other biologic and biosimilar markets, but regulatory challenges and market inertia may delay widespread adoption.
Impacts of New Regulations
Recent healthcare reforms focused on generic drug affordability, including REMS (Risk Evaluation and Mitigation Strategies) adjustments and FDA initiatives, could influence the supply chain and hence pricing. Additionally, drug shortages driven by manufacturing disruptions could temporarily inflate prices but are unlikely to impact long-term pricing trajectories significantly.
Distribution and Procurement Strategies
Healthcare providers are increasingly leveraging group purchasing organizations (GPOs) to negotiate better prices, while hospitals shift towards bulk purchasing to capitalize on economies of scale. The trend towards outpatient infusion services also impacts distribution channels, influencing cost structures.
Price Projections (2023–2030)
Based on current market forces, historical trends, and regulatory landscapes, the price trajectory for NDC 00003-0524 (cytarabine injection) can be summarized as follows:
| Year | Price Range per 1,000 mg vial | Key Factors |
|---|---|---|
| 2023 | $50–$70 | Saturation of generic market; stable demand |
| 2025 | $45–$65 | Slight further reductions; increased biosimilar activity |
| 2027 | $40–$60 | Potential biosimilar entry gaining traction |
| 2030 | $35–$55 | Market maturation; continued cost pressures |
The downward trend reflects sustained generic competition, procurement efficiencies, and a shift towards cost-effective oncology treatments.
Strategic Considerations for Stakeholders
- Manufacturers should focus on securing patent protections or innovative formulation enhancements to extend market exclusivity.
- Healthcare providers can leverage GPO negotiations and formulary placements to obtain optimal pricing.
- Investors should monitor biosimilar developments and regulatory shifts, which could accelerate price erosion.
- Regulators must balance reducing costs and ensuring supply stability, especially amidst manufacturing disruptions.
Key Takeaways
- NDC 00003-0524, representing cytarabine injection, operates in a highly competitive, cost-sensitive market.
- Price decline from approximately $250 to $50 per vial over the past decade highlights significant generic entry and market maturation.
- Market growth is supported by increasing hematologic cancer prevalence, but emerging therapies and biosimilars pose future price pressures.
- Strategic procurement and regulatory developments are critical levers influencing price trajectories.
- Projections suggest continued moderate price declines through 2030, emphasizing the importance of early innovation and strategic positioning.
FAQs
1. What factors are most influential in determining the price of cytarabine injections?
Market competition from generics, regulatory environment, procurement strategies, and the overall prevalence of hematologic cancers significantly impact pricing.
2. How does biosimilar entry affect the market for NDC 00003-0524?
Biosimilars can introduce additional competition, potentially accelerating price reductions but are currently limited for cytarabine, pending regulatory approval and market acceptance.
3. Are there significant regional variations in pricing for this drug?
Yes. In the U.S., negotiated discounts, formulary preferences, and supply chain dynamics cause price variability across different healthcare settings and regions.
4. What future trends could impact the demand for cytarabine?
Advancements in targeted therapies, immunotherapies, and personalized medicine could shift treatment paradigms, affecting demand levels for cytarabine.
5. How can manufacturers extend the lifecycle of this drug?
Innovative formulations, combination therapies, or patent strategies could help preserve market share amid evolving treatment options.
References
- American Cancer Society. "Cancer Facts & Figures 2022."
- SSR Health. "Average Wholesale Price Trends for Cytarabine," 2022.
- FDA. "Generic Drug Development and Approval," 2023.
- IQVIA. "Market Insights on Oncology Drugs," 2022.
- Specialty Pharmaceutical Reports. "Biosimilar Entry and Market Impact," 2022.
Note: Price projections and market data are estimates based on current trends and may vary with market developments, regulatory changes, and innovations.
More… ↓
